ABSTRACT: On the basis of the long-known prototypic pharmacophore 3-(1H-imidazol-4-yl)propylguanidine (SK&F 91486, 2), monomeric, homodimeric, and heterodimeric bisalkylguanidine-type histamine H 2 receptor (H 2 R) agonists with various alkyl spacers were synthesized. Aiming at increased H 2 R selectivity of the ligands, the imidazol-4-yl moiety was replaced by imidazol-1-yl, 2-aminothiazol-5-yl or 2-amino-4-methylthiazol-5-yl according to a bioisosteric approach. All compounds turned out to be partial or full agonists at the h/gp/rH 2 R. The most potent analogue, the thiazole-type heterodimeric ligand 63 (UR-Po461), was a partial agonist (E max = 88%) and 250 times more potent than histamine (pEC 50 : 8.56 vs 6.16, gpH 2 R, atrium). The homodimeric structures 56 (UR-Po395) and 58 (UR-Po448) exhibited the highest hH 2 R affinities (pK i : 7.47, 7.33) in binding studies. Dimeric amino(methyl)thiazole derivatives, such as 58, generated an increased hH 2 R selectivity compared to the monomeric analogues, e.g., 139 (UR-Po444). Although monomeric ligands showed up lower affinities and potencies at the H 2 R, compounds with a short alkylic side chain like 129 (UR-Po194) proved to be highly affine hH 4 R ligands.
INTRODUCTION
In humans, the histamine receptor family comprises four subtypes, namely, H 1 , H 2 , H 3 , and H 4 receptors. 1−4 They are activated by the biogenic amine histamine (1, Figure 1 ) 5 and belong to the superfamily of G-protein-coupled receptors (GPCRs). 6 For more than three decades, 3-(1H-imidazol-4-yl)propylguanidine (SK&F 91486, 2, Figure 1 ) 7 has been used as prototypic pharmacophore for the synthesis of highly potent histamine H 2 -receptor (H 2 R) agonists of the guanidine class, e.g., compounds such as arpromidine (3, Figure 1 ). 8 The application of the bivalent ligand approach to acylguanidinetype H 2 R agonists by Birnkammer et al. led to highly potent and selective H 2 R agonists, e.g., UR-AK 381 (4, Figure 1 ), raising questions about the binding mode and usability of such dimeric ligands as pharmacological tools. 9 Insufficient chemical stability of these acylguanidines, due to hydrolytic cleavage, led to carbamoylguanidine-type H 2 R agonists, which proved to be stable. 10 As many class A GPCRs were reported to form homoand heterodimers, bivalent ligands can potentially be used as pharmacological tools to investigate the binding mode. 11, 12 Using different spacer lengths, Birnkammer et al. showed that an interaction of the second pharmacophore with an allosteric binding site at the same receptor protomer is more likely than binding to the second orthosteric binding site of an H 2 R homodimer. 9 For a better understanding of the structure−activity relationship of bisalkylguanidine-type dimeric H 2 R ligands, we prepared and pharmacologically characterized several monomeric and dimeric compounds derived from the recently reported homodimeric H 2 R agonist SK&F 93082 (5, Figure  1) . 13 In particular, the influence of different heteroaromatic ring systems and different spacer lengths on histamine receptor subtype selectivity was studied, using radioligand binding assays to investigate the affinities to the respective receptors. Investigations on H 2 R species selectivity were performed involving recombinant human, guinea pig, and rat H 2 Rs ([ 35 S]GTPγS binding assay), 14 which gave information about the type, affinity/potency, and efficacy of the receptor ligand. Organ pharmacological studies (gpH 1 R (ileum), gpH 2 R (right atrium)) 15, 16 afforded agonistic (H 2 R) and antagonistic (H 1 R) activities under more physiological conditions. Functional activities on the guinea pig ileum and right atrium were measured via the contractility of the tissue and the increase of the heart frequency, respectively. The main focus of this project was the development of H 2 R agonists. This also includes the characterization of numerous compounds at the other histamine receptors (H 1,3,4 R), which led to the identification of selective H 4 R ligands.
RESULTS AND DISCUSSION
2.1. Chemistry. The structures of amines 6−9, which were used for the synthesis of compounds 5, 53−63, 127−141, and 145, are depicted in Figure 2 . For the preparation of the dimeric ligands, the diamines 11−16 were treated with benzoyl isothiocyanate (10) to give the corresponding dibenzoylthioureas 17−22 (Scheme 1) via nucleophilic addition, followed by alkaline hydrolysis yielding the bisthioureas 23−28 as described. 17, 8 After S-methylation using methyl iodide, the bis(S-methylisothioureas) 29−34 were Boc-protected to give the guanidinylation reagents 35−40 (Scheme 1) following reported procedures. 8, 18 The homodimeric ligands 5, 53−60 were obtained by treating amines 6, 7, 8, or 9 (each 2 equiv) with some of the guanidinylation reagents 35−40 in the presence of HgCl 2 (2 equiv) and triethylamine (NEt 3 ), 19 followed by Boc deprotection of the intermediates 41−49. The heterodimeric ligands 61−63 were synthesized by treatment of the guanidinylating reagent 38 with an equimolar mixture of two different amines (6 and 7, 6 and 8, or 7 and 8), followed by deprotection of the intermediates 50−52 using trifluoroacetic acid (TFA, Scheme 1). It should be mentioned that the use of more than 2 equiv of HgCl 2 led to a decrease in yield, presumably due to conversion of one S-methylisothiourea moiety to the respective carbodiimide as described in the literature. 18, 19 The synthetic strategy for the dimeric compounds was also used for the synthesis of the monomeric compounds 127−141 (Scheme 2). Although the alkylated thioureas 82−87 were commercially available, 76−81 had to be synthesized by nucleophilic addition of the corresponding amine (64−69) with 10 to give 70−75, followed by alkaline hydrolysis yielding the desired compounds (cf. Scheme 2). S-methylation (88− 99), Boc-protection (100−111), and guanidinylation (112− 126) were accomplished as described for the dimeric ligands with adapted amount of substance (Scheme 2). Finally, the precursors 112−126 were deprotected using TFA to give 127− 141 (Scheme 2).
The cyclic guanidine derivative N-[3-(1H-imidazol-4-yl)-propyl]-1,4,5,6-tetrahydropyrimidin-2-amine (145) was prepared in a three-step synthesis starting from tetrahydropyrimidine-2(1H)-thione (142) (Scheme 3). Di-Boc-protection of 142 in the presence of sodium hydride resulted in 143 (Scheme 3), as described. 20 After guanidinylation with 6, intermediate 144 was treated with TFA to receive 145 (Scheme 3).
2.2. Stability of Dimeric Alkylguanidines. The chemical stability of the bisalkylguanidine-type dimeric HR ligands was exemplarily investigated for compounds 57 and 58, which were incubated in a binding buffer (BB, pH 7.4) at a concentration of 100 μM at room temperature for 12 months. Reversed-phase high-performance liquid chromatography (RP-HPLC) analysis revealed that 57 and 58 exhibited, in contrast to the previously reported acylguanidine-type HR ligands, 10 excellent chemical stabilities ( Figure 3 4 R). The imidazol-4-yl-type homodimeric ligands 56 and 57, containing a decamethylene and a dodecamethylene spacer, respectively, exhibited the highest affinities at every HR subtype with the following selectivity profile: pK i H 1 R < H 2 R ≈ H 3 R ≈ H 4 R ( Table 1 ). The same selectivity profile was evident for the homodimeric compounds 5 and 53−55. The 2-amino-4-methylthiazol-5-yl-and 2-aminothiazol-5-yl-type homodimeric ligands 58 and 59, respectively, as well as the 2-amino-4-methylthiazol-5-yl/2-aminothiazol-5-yl-type heterodimeric compound 63 proved to be selective H 2 R ligands with at least 1.5 log units difference in pK i (H 2 R) over pK i (H 1,3,4 R) ( Table 1) . This demonstrated that replacement of the imidazol-4-yl by an 2-aminothiazol-5-yl moiety is bioisosteric with respect to H 2 R binding, but not in case of H 3 and H 4 receptor binding, and was in accordance with previous reports on 2-aminothiazol-5-yl-type H 2 R selective ligands. 22 The binding data at the hH 1 R showed values, which were dependent from the spacer length, respectively the lipophilicity. The replacement of imidazol-4-yl by a imidazol-1-yl ring (60) leads to a collapse of the affinities at all histamine receptor subtypes. The monomeric reference substances 127− 141 and 145 displayed increasing affinities at the hH 2 R with respect to their chain length, but lower affinities compared to the respective dimeric compounds. Overall, the affinities at the hH 3,4 Rs were higher, except of the aminothiazole-containing structures 139−140. Molecules with a small side chain like 129 are of special interest as highly affine hH 4 R ligands. Sigmoidal radioligand displacement curves at all HR subtypes are shown for 58, which exhibited the highest H 2 R selectivity ( Figure 4 Table 2 ). Antagonistic activities at the hH 4 R were throughout low (pK B < 4). 2.3.3. H 2 R Species Selectivity. To study the H 2 R species selectivity of the bisalkylguanidine-type dimeric ligands, the agonistic activities of compounds 5, 57, 58, and 63 were also investigated at the gpH 2 R and rH 2 R in the GTPγS binding assay. The studied compounds exhibited slightly higher agonistic potencies at the gpH 2 R and rH 2 R compared to the hH 2 R, with pEC 50 values >7.2 and >6.8, respectively (Table 3) . Compound 5 showed the highest gpH 2 R potency (pEC 50 = 7.60) with a high efficacy (E max = 0.95), and 57 displayed the highest rH 2 R potency (pEC 50 = 7.61) with an efficacy of 0.80. In general, the efficacies were considerably higher at the gpH 2 R and rH 2 R (E max > 0.7) compared to the hH 2 R (E max < 0.52), reaching full agonism in case of compound 63 (gpH 2 R, E max = 1.02). In sum, these investigations revealed that the highest potencies and efficacies were observed at the gpH 2 R followed by the rH 2 R and the hH 2 R.
2.3.4. Organ Bath Studies. In addition to the pharmacological characterization by radioligand competition binding (cf. Table 4 ). Overall, a switch from monomeric to dimeric ligands revealed compounds, which are approximately 100 times more potent than their monomeric analogues. The concentration− response curve (CRC) of 63 (atrium, gpH 2 R) is exemplarily shown in Figure 5A .
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The maximum response of all H 2 R agonists at the right atrium could be completely antagonized by the addition of the H 2 R antagonist cimetidine (pA 2 = 6.10 25, 26 ) (30 μM) after cumulative organ stimulation (63, cf. Figure 5A ). Full CRCs in the presence of cimetidine (30 μM, 30 min preincubation) were obtained for compounds 5, 57, 62, 63 ( Figure 5B) , 127, 128, 132, 135, and 137. The presence of cimetidine led to a rightward shift of the CRCs in a way that is in accordance with the calculated values via Schild equation (Table S1 , Supporting Information). These results proved that the positive chronotropic effect of the investigated (partial) agonists in the guinea pig right atrium assay was mediated via the H 2 R.
2.4. Computational Studies. To determine accurate binding modes of the most interesting bivalent compounds 5 and 58 at the hH 2 R, and of the monovalent ligand 129 at both the hH 3 R and hH 4 R, molecular docking studies were performed, coupled with molecular dynamics (MD) simulations and free-energy (molecular mechanics generalized born surface area (MM-GBSA)) calculations. Overall, five promising binding poses for 5 and 58 at the hH 2 R, two poses for 129 at the hH 3 R, and three poses for 129 at the hH 4 R were determined by docking studies. Visual analysis of ligand− receptor complexes refined by molecular dynamics simulations (30 ns) has shown that some poses primarily formed contacts within the orthosteric binding site, whereas other poses additionally interacted with residues of the allosteric site between extracellular loop (ECL)2 and ECL3 (Figures S29− S31 and Table S3 7 , and S28). Interestingly, compared to the other poses, these lowest free-energy conformations were among those with the strongest H-bond contacts between ligand atoms and acidic amino acids of the orthosteric binding site (D98 3.32 , D186
5.42 for 5 and 58 at hH 2 R, D114 3.32 for 129 at hH 3 R, and Figure S32 ). The probability for an interaction with these residues is supported by the fact that they were proven to act as key player in aminergic GPCR activation and ligand binding, 27−30 or to account for receptor selectivity (D186 5.42 at hH 2 R). 31 Interestingly, both 5 and 58 showed high binding affinities at hH 2 R (K i < 100 nM), low affinities at the hH 1 R (K i > 1 μM), but varying affinities at the hH 3 R and hH 4 R (5: K i < 100 nM; 58:
Although, by contrast, the monomeric imidazole-type analogue 129 bound unexpectedly poor to the hH 2 R, and, comparable to the dimeric compounds, also to the hH 1 R (K i > 1 μM), it bound to the hH 3 R and hH 4 R with high affinity (K i < 100 nM). In this context, an amino(methyl)-thiazole moiety present in 58, unlike an imidazole moiety present in 5 or 129, was shown to trigger hH 2 R selectivity also in the case of other ligands. 32, 33 Aiming at an attempt to explain this behavior, different steric effects of amino acids enclosing the orthosteric binding pocket may come into play due to less voluminous residues at the hH 2 R (V99 5.42 ) may further contribute to hH 2 R selectivity of amino(methyl)thiazole-type compounds, but to preferential binding of imidazole-type ligands, such as 5 or 129, to the hH 3 R and hH 4 R. Although 5 is still capable of binding to hH 2 R, most probably due to its larger and more flexible chain, 129 merely binds to the hH 3 R and hH 4 R with high affinity in a welldefined binding mode. Noteworthy, the lowest free-energy pose (pose 1) of 129 bound to the hH 4 R showed H-bond contacts with E163
ECL2 and T178 5.42 in addition to contacts with D94 3.32 and E182 5.46 , compared to relatively few and weak H-bond interactions when bound to hH 3 R (Figures 7 and S32 ). This may contribute to a lower 129 binding free energy when bound to the hH 4 R, compared to hH 3 R ( Figure S28 ).
SUMMARY AND CONCLUSIONS
Homo-(5 and 53−60) and heterodimeric (61−63) as well as monomeric (127−141 and 145) hetarylpropylguanidine-type HR ligands were obtained in excellent yield by a six-step synthesis. The replacement of the imidazolyl by an aminothiazolyl moiety led, in accordance with previous reports on acylguanidine-and carbamoylguanidine-type HR ligands, 9, 10, 22 to highly selective and potent H 2 R agonists. The variation of the spacer length revealed best results for compounds containing a C 8 -, C 10 -, or C 12 -spacer (5, 56−59, and 61−63). The heterodimeric compounds showed potencies in a one-digit nanomolar range (up to 250 times the potency of histamine) as full agonists in the gpH 2 R atrium assay. In comparison to the monomeric ligands, the dualsteric structures showed up notably higher hH 2 R selectivity, higher affinities in the hH 2 R binding assay, and higher potencies at the functional H 2 R assays (e.g., guinea pig right atrium). The dimeric ligands displayed a slightly higher sensitivity for gpH 2 R and rH 2 R compared to the as key contributions to H 2 R binding. As the bisalkylguanidines turned out to be very stable chemical entities, the synthesized H 2 R selective aminothiazole derivatives represent promising lead structures for the development of pharmacological tools for the H 2 R, such as 58, 59, and 63. Moreover, the presented data could be of interest for the development of CNS penetrating H 2 R agonistsin consideration of changing the basicity of the strongly basic alkylguanidine structure, using e E max : maximal response relative to the maximal increase in heart rate induced by histamine (E max = 1.00).
f n.a. = not active. 
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Article bioisosteric approaches, and the lipophilicityand H 2 R ligands useful for the treatment of acute myeloid leukemia. Commercially available chemicals (9, 10, 11−16, 64−69, and 82−87) and solvents were purchased from Acros Organics (Geel, Belgium), Alfa Aesar GmbH & Co. KG (Karlsruhe, Germany), Iris Biotech GmbH (Marktredwitz, Germany), Merck KGaA (Darmstadt, Germany), Sigma-Aldrich Chemie GmbH (Munchen, Germany), or TCI Europe (Zwijndrecht, Belgium) and were used as received. Deuterated solvents for nuclear magnetic resonance ( 1 H NMR and 13 C NMR) spectra were purchased from Deutero GmbH (Kastellaun, Germany). Compounds 6−8 were prepared as previously described. 22, 32, 36, 37 The synthesis steps described in Section 2.1 were carried out according to reported procedures. 8,17−19 All reactions involving dry solvents were accomplished in dry flasks under nitrogen or argon atmosphere. Millipore water was used for the preparation of buffers, HPLC eluents, and stock solutions. Column chromatography was carried out using Merck silica gel Geduran 60 (0. 13 C: 101 MHz) spectrometer using perdeuterated solvents. The chemical shift δ is given in parts per million (ppm). Multiplicities were specified with the following abbreviations: s (singlet), d (doublet), t (triplet), q (quartet), quint (quintet), m (multiplet), and br (broad signal) as well as combinations thereof. 13 C NMR peaks were determined by distortionless enhancement by polarization transfer (DEPT) 135 and DEPT 90: "+" primary and tertiary carbon atom (positive DEPT 135 signal), "−" secondary carbon atom (negative DEPT 135 signal), and "quat" quaternary carbon atom. NMR spectra were processed with MestReNova 11.0 . Capacity factors were calculated according to k = (t R − t 0 )/t 0 . Detection was performed at 220 nm. All compounds were analyzed using method A, except for 139− 141 (method B). Furthermore, filtration of the stock solutions with poly(tetrafluoroethylene) filters (25 mm, 0.2 μm, Phenomenex Ltd., Aschaffenburg, Germany) was accomplished before testing. Compound purities determined by HPLC were calculated as the peak area of the analyzed compound in % relative to the total peak area (UV detection at 220 nm). The HPLC purities (see Supporting Information) of the final compounds were ≥95% except for compound 58 (94.3%). The tested compounds were screened for pan-assay interference compounds (PAINS) and aggregation by publicly available filters (http://zinc15.docking.org/patterns/home, http:// advisor.docking.org). 38, 39 None of the screened structures have been previously reported as PAINS or an aggregator. Since Devine et al. described 2-aminothiazoles as a promiscuous frequent hitting scaffold at different enzymes, 40 full dose− response curves for all experiments and compounds, not only for the 2-aminothiazoles, were measured. None of the curves showed abnormalities, e.g., high Hill slopes, which could be a hint for PAINS. To an ice-cold solution of the pertinent diamine (11−16, 1 equiv) in dichloromethane (DCM), benzoyl isothiocyanate (2 equiv) in DCM was added dropwise. The reaction was allowed to stir at room temperature (rt) overnight, and the organic solvent was concentrated under vacuum. The residue was suspended in 80 mL of methanol (MeOH) for 1 h and filtered to give the pure title compound. 4.2.6. General Procedure for the Guanidinylation Reaction of 50−52. To a suspension of the corresponding amine 6, 7, or 8 (two out of them, each 1 equiv), 38 (1 equiv), and HgCl 2 (2 equiv) in DCM, NEt 3 (6 equiv) was added. The mixture was stirred overnight at rt. A possible excess of HgCl 2 was quenched with 7 N NH 3 in MeOH (3−5 mL). The resulting suspension was filtered over Celite, and the crude product was used in the next step without further purification. 50 (m, 4H), 1.46−1.30 (m, 8H) . 13 C NMR (75 MHz, CD 3 OD, tetra-trifluoroacetate) δ (ppm) 171.7, 170.3, 157.5,  132.4, 126.7, 123.7, 118.9, 43.1, 42.0, 41.9, 31.0, 30.8, 30.4 To an ice-cold solution of the pertinent amine (64−69, 1 equiv) in MeCN, benzoyl isothiocyanate (1 equiv) was added dropwise. The reaction was stirred at room temperature (rt) for 2 h, and the organic solvent was concentrated under vacuum. The residue was dissolved in DCM (50 mL) and washed three times with H 2 O and saturated solution of NaCl. The organic layer was dried over Na 2 SO 4 , and the crude product was purified by column chromatography (EtOAc/PE 1/9−1/6 v/v).
4.2.8.1. N-(Isobutylcarbamothioyl)benzamide (70) . 42 The title compound was prepared from isobutylamine (64, 1.00 mL, 10.00 mmol) and 10 (1.34 mL, 10.00 mmol) in MeCN 4.2.9. General Procedure for the Synthesis of the Thioureas 76−81. The corresponding benzoylthiourea (70− 75, 1 equiv) was stirred in a solution of K 2 CO 3 (2.1 equiv) in MeOH/H 2 O (7/3 v/v) for 3−5 h at rt. The proportion of MeOH was evaporated, and the resulting suspension was extracted with DCM and stirred for 1 h. The organic layer was dried over Na 2 SO 4 , and the crude product was purified by column chromatography (DCM/MeOH/7M NH 3 in MeOH 95/3/2 v/v).
Because of the thione−thiol tautomerism, a splitting of the NH−CH 2 −R-signal could be observed in the following NMR spectra. Two broad singlets could be noted right next to each other. In each case, the integration value was exactly 2. For all of the other symmetric CH 2 peaks, this peak splitting was not shown.
4.2.9.1. N-Isobutylthiourea (76) . 42 The title compound was prepared from 70 (2.00 g, 8. 4.2.14. Synthesis of Di-tert-butyl-2-thioxodihydropyrimidin-1,3(2H,4H)-dicarboxylat (143). 45 To a stirred solution of 142 (871 mg, 7.50 mmol) in THF (150 mL) under argon at 0°C
, hexane (20 mL) and sodium hydride (1.35 g, 33.8 mmol, 60% in mineral oil) were added. After 5 min, the ice bath was removed, and the reaction mixture was stirred at room temperature for 10 min. The mixture was cooled to 0°C again, di-tert-butyl dicarbonate (3.60 g, 16.5 mmol) was added, and the ice bath was removed after 30 min of stirring at that temperature. The resulting slurry was stirred for another 2 h at room temperature. Then, the reaction was quenched with an aqueous solution of saturated NaHCO 3 (10 mL). The reaction mixture was poured into water (250 mL) and extracted with EtOAc (3 × 70 mL). The combined organic layer was dried over Na 2 SO 4 , filtered, and concentrated in vacuo to give 143 as a yellow solid (1.88 g, 79%), mp 84.7°C. 1 H NMR (300 MHz, CDCl 3 ) δ (ppm) 3.67 (t, J = 6.9 Hz, 4H), 2.15 (quint, J = 6.9 Hz, 2H), 1.53 (s, 18H). 13 KG, Schwabach, Germany). Afterward, bound radioligand was separated from free radioligand by filtration through GF/C filters (Whatman, Maidstone, U.K.) using a 96-well Brandel harvester (Brandel Inc., Unterfoḧring, Germany). After two washing steps with binding buffer, the filter pieces were punched and transferred into 1450-401 96-well sample plates (PerkinElmer). Unspecific binding was determined in the presence of 10 μM GTPγS. Each well was supplemented with 200 μL of scintillation cocktail (Rotiszint Eco plus, Roth, Karlsruhe, Germany), and the plates were sealed with Plateseal 1450-461 (PerkinElmer, Rodgau, Germany) and incubated in the dark for 12 h. Radioactivity (ccpm) was measured with a MicroBeta 2 1450 scintillation counter (PerkinElmer). Data were analyzed by nonlinear regression and were best-fitted to sigmoidal concentration−response curves with the Prism 5.0c software (GraphPad, San Diego, CA).
4.3.5. Histamine H 1 Receptor Assay on Isolated Guinea Pig Ileum. 15 Guinea pigs of either sex (250−500 g) were stunned by a blow on the neck and exsanguinated. The ileum was rapidly removed, rinsed, and cut into segments of 1.5−2.0 cm length. The tissues were mounted isotonically (preload of 5 mN) in a jacketed 20 mL organ bath that was filled with Tyrode's solution (composition [mM]: NaCl, 137; KCl, 2.7; CaCl 2 , 1.8; MgCl 2 , 1.0; NaH 2 PO 4 , 0.4; NaHCO 3 , 11.9; and glucose 5.0) supplemented with atropine, at a concentration not affecting H 1 receptors (0.05 μM), to block cholinergic muscarinic receptors. The bath was aerated with 95% O 2 /5% CO 2 and heated to 37°C. During an equilibration period of 80 min, the tissues were stimulated three times with histamine (2 × 1 μM, 1 × 10 μM) followed by washout. Up to four cumulative CRCs were determined on each tissue: the first by addition of histamine (0.01−30 μM) and the second to fourth by addition of histamine in the presence of increasing concentrations of antagonist (preincubation: 10−15 min). pEC 50 differences were not corrected because four successive curves for histamine were superimposable under these conditions (N > 10). Data were analyzed by nonlinear regression and were best-fitted to sigmoidal concentration− response curves using Prism 5.0c software (GraphPad, San Diego, CA).
4.3.6. Histamine H 2 Receptor Assay on the Isolated Guinea Pig Right Atrium (Spontaneously Beating). 2, 16, 53 Hearts were rapidly removed from guinea pigs used for studies on the ileum (see above). The right atrium was quickly dissected and set up isometrically in the Krebs−Henseleit solution under a diastolic resting force of approximately 5 mN in a jacketed 20 mL organ bath at 32.5°C. The bath fluid (composition [mM]: NaCl, 118.1; KCl, 4.7; CaCl 2 , 1.8; MgSO 4 , 1.64; KH 2 PO 4 , 1.2; NaHCO 3 , 25.0; glucose, 5.0; sodium pyruvate, 2.0), supplemented with (RS)-propranolol (0.3 μM) to block β-adrenergic receptors, was equilibrated with 95% O 2 and 5% CO 2 . Experiments were started after 30 min of continuous washing and an additional equilibration period of 15 min. Two successive histamine CRCs displayed a significant desensitization of 0.13 ± 0.02 (N = 16 control organs). This value was used to correct each individual experiment. For agonists, two successive concentration−frequency curves were generated: the first for histamine (0.1−30 μM) and the second for the agonist of interest either in the absence or in the presence of cimetidine (30 μM, 30 min preincubated). Additionally, the sensitivity to 30, 100, or 300 μM cimetidine was checked at the end of each H 2 R agonist CRC, and a significant reduction of frequency was observed. The relative potency of the agonist under study was calculated from the corrected pEC 50 difference (ΔpEC 50 ). pEC 50 values are given relative to the long-term mean value for histamine (pEC 50 = 6.16) determined in our laboratory (pEC 50 = 6.16 + ΔpEC 50 ). Data were analyzed by nonlinear regression and were best-fitted to sigmoidal concentration−response curves using Prism 5.0c software (GraphPad, San Diego, CA).
4.4. Computational Methods. 4.4.1. Model Preparation. To examine possible binding modes of the bivalent ligands 5 and 58 at hH 2 R and of the monovalent ligand 129 at both hH 3 R and hH 4 R, homology models of these receptors were prepared as follows: For hH 4 R, the described hH 4 R model was used, 54 which was based on the inactive state crystal structure of the hH 1 R 55 (PDB ID: 3RZE), and the models comprising hH 2 R and hH 3 R were adapted from this model. Model preparation was essentially performed as described in Wifling et al. 54 using the modeling suite SYBYL-X 2.0 (Tripos Inc., St. Louis, MO).
4.4.2. Molecular Docking. The most interesting bivalent compounds 5 and 58 on the one hand and the monomeric ligand 129 on the other hand were geometry-optimized by means of Gaussian 09 56 at the HF/6-31(d,p) level, attributing the ligands a formal charge of +2 and +1, respectively. Upon file conversion by means of Open Babel 57 and assignment of physiological ionization states by means of ChemAxon (http:// www.chemaxon.com) Marvin 16.3.28.0, 2016 Calculator Plugins, flexible docking was performed with the software package Autodock Vina. 58 The following hH 2 R amino acids were kept as flexible: K18, S75, Q79, Y94, T95, D98, V99, C102, R161, N168, H169, T170, T171, S172, K173, K175, V176, V178, N179, E180, G183, D186, G187, T190, W247, Y250, F251, F254, R257, R260, N266, E267, E270, L274, W275, G277, Y278. For hH 3 R, the amino acids T34, M41, Y91, Y94, V95, W110, L111, D114, Y115, C118, E185, H187, F192, F193, Y194, W196, L199, A202, S203, E206, W371, Y374, T375, M378, R381, H387, D391, D394, E395, D398, W399, L401, W402 were kept as flexible, and for hH 4 R the residues R15, M22, Y72, H75, T76, W90, L91, D94, Y95, C98, M150, K158, E160, S162, E163, F168, F169, S170, W172, L175, T178, S179, E182, W316, Y319, S320, T323, L326, S330, S331, T333, S337, Y340, R341, F344, W345, Q347, W348. The search box was set to a size of 28 Å × 32 Å × 32 Å, centered at the binding pocket. Up to 20 binding poses were exported for each ligand. Taking into account the results of the scoring function as well as experimental data, the respective best poses were selected for downstream molecular dynamics simulations.
4.4.3. Molecular Dynamics Simulations. To identify the respective most probable binding pose, 30 ns molecular dynamics simulations were performed in a water box at 310 K, and subsequently, free energy (MM-GBSA 59 ) calculations were performed using the Amber 14 60 molecular dynamics package. To determine ligand force-field parameters, RESP 61 charges were determined by means of Gaussian 09 56 at the HF/ 6-31(d,p) level, and general amber force field 62 atom types as well as RESP 61 charges were assigned using antechamber. 60 parmchk2 60 and tleap 60 were used for input file generation. For ligand guanidine atoms and protein residues, the Amber ff99SB 63 force-field parameters were used. The simulation steps were carried out in an octahedral box comprising an 8.0 Å TIP3P 64 water layer and neutralizing chloride ions. 65 The mbondi2 parameter set was utilized. 66, 67 The respective systems were minimized using the steepest descent (2500 steps) and conjugated gradient (7500 steps) methods without restraints, and were subsequently heated from 0 to 100 K over 50 ps in the NVT ensemble as well as from 100 to 310 K over 450 ps in the NPT ensemble. During the first ns of the 5 ns equilibration period, initial harmonic restraints of 5 kcal/mol Å 2 were applied to all ligand and receptor atoms, and, beginning from 1 ns, harmonic restraints on receptor main chain atoms were reduced from 5.0 to 0.5 kcal/mol Å 2 in a stepwise manner and maintained during the 30 ns simulation. Bonds involving hydrogen atoms were constrained using SHAKE 68 to enable a frame step size of 2 fs. 65, 69 Nonbonded interactions were cut off at 8.0 Å, and long-range electrostatics were computed using the particle-mesh Ewald 70 method. The Langevin thermostat 71, 72 with a collision frequency of 1.0 ps −1 and randomly assigned initial velocities was used to maintain a target temperature of 310 K. The Berendsen barostat 73 with isotropic position scaling and a pressure relaxation time of 1.0 ps was employed to keep the pressure constant at 1 bar. Data were collected every 10 ps. H-bond and cluster analysis were performed by means of CPPTRAJ 60 for the entire 30 ns trajectories. Moreover, the average linkage algorithm 74 was applied for cluster analysis, setting a cluster size of 5, and the programming language R 75−78 was used for the preparation of H-bond plots. Binding free-energy (MM-GBSA) calculations of the 30 ns trajectories were performed using MMPBSA.py 59 and a frame step size of 10 ps, and the corresponding plots were obtained using the Prism 5.01 software (GraphPad, San Diego, CA). All other figures were created with PyMOL Molecular Graphics system, version 1.8. 
